This sounds really positive upcoming.
The oral presentation will announce the substantially improved overall response rate, as advised 27
June 2024, and additional data in patients with first line head and neck squamous cell carcinoma who have
negative PD-L1 (Cohort B).
Ann: Details for Immutep Webcast & ESMO Virtual Plenary Session, page-4
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
32.0¢ |
Change
-0.015(4.48%) |
Mkt cap ! $464.8M | |||
| Open | High | Low | Value | Volume |
| 32.0¢ | 32.8¢ | 31.5¢ | $1.587M | 4.950M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 35998 | 32.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 32.5¢ | 286931 | 7 |
View Market Depth
| Last trade - 16.10pm 02/10/2024 (20 minute delay) ? |
| IMM (ASX) Chart |